Associations between histologic features of Nonalcoholic Fatty Liver Disease (NAFLD) and quantitative diffusion-weighted MRI measurements in adults

Journal of Magnetic Resonance Imaging

Volumn 41, Issue 6, 2015, Pages 1629-1638

  Murphy, Paul ^a   Hooker, Jonathan ^a   Ang, Brandon ^b   Wolfson, Tanya ^c   Gamst, Anthony ^c   Bydder, Mark ^a   Middleton, Michael ^a   Peterson, Michael ^d   Behling, Cynthia ^e   Loomba, Rohit ^b,f   Sirlin, Claude ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Western Washington Pathology   (United States)

^e Pacific Rim Pathology Medical Corporation   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

diffusion; DWI; IVIM; liver; NAFLD; NASH

Indexed keywords

ADULT; AGED; ARTICLE; CONVENTIONAL MAGNITUDE AVERAGING; CROSS-SECTIONAL STUDY; DIFFUSION; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; DISEASE ASSOCIATION; FATTY LIVER; FEMALE; HEPATITIS; HUMAN; IMAGE RECONSTRUCTION; LIVER FIBROSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE SCANNER; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; BIOPSY; COMPUTER ASSISTED DIAGNOSIS; MIDDLE AGED; PATHOLOGY; PROCEDURES;

ADULT; AGED; BIOPSY; CROSS-SECTIONAL STUDIES; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PROSPECTIVE STUDIES;

EID: 84930044693     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.24755     Document Type: Article

References (34)

1. Chalasani N, Younossi Z, Lavine JE, et al., The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-2023.
2. Loomba R, Abraham M, Unalp A, et al., Association between diabetes, family history of diabetes and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology 2012; 56: 943-951.
3. Loomba R, Sanjal A,. The global NAFLD epidemic. Nat Rev Hepatol 2013; 10: 686-690.
4. Noureddin M, Lam J, Peterson MR, et al., Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology 2013; 58: 1930-1940.
5. Kleiner DE, Brunt EM, Van Natta M, et al., Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321.
6. Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA,. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 2011; 53: 810-820.
7. Stinton L, Loomba R,. Recommendations for liver biopsy evaluation in non-alcoholic fatty liver disease. Minerva Gastroentol Dietol 2014; 60: 5-13.
8. Taouli B, Koh D-M,. Diffusion-weighted MR imaging of the liver. Radiology 2010; 254: 47-66.
9. Joo I, Lee JM, Yoon JH, Jang JJ, Han JK, Choi BI,. Nonalcoholic fatty liver disease: intravoxel incoherent motion diffusion-weighted MR imaging-an experimental study in a rabbit model. Radiology 2014; 270: 131-140.
10. Anderson SW, Soto JA, Milch HN, et al., Effect of disease progression on liver apparent diffusion coefficient values in a murine model of NASH at 11.7 Tesla MRI. J Magn Reson Imaging 2011; 33: 882-888.
11. Hansmann J, Hernando D, Reeder SB,. Fat confounds the observed apparent diffusion coefficient in patients with hepatic steatosis. Magn Reson Med 2013; 69: 545-552.
12. Poyraz AK, Onur MR, Kocakoç E, Oʇur E,. Diffusion-weighted MRI of fatty liver. J Magn Reson Imaging 2012; 35: 1108-1111.
13. Eatesam M, Noworolski SM, Tien PC, et al., Liver diffusivity in healthy volunteers and patients with chronic liver disease: comparison of breathhold and free-breathing techniques. J Magn Reson Imaging 2011; 35: 103-109.
14. Guiu B, Petit J-M, Capitan V, et al., Intravoxel incoherent motion diffusion-weighted imaging in nonalcoholic fatty liver: a 3.0-T MR study. Radiology 2012; 265: 96-103.
15. Leitão HS, Doblas S, d'Assignies G, et al., Fat deposition decreases diffusion parameters at MRI: a study in phantoms and patients with liver steatosis. Eur Radiol 2013; 23: 461-467.
16. Taouli B, Chouli M, Martin AJ, Qayyum A, Coakley FV, Vilgrain V,. Chronic hepatitis: role of diffusion-weighted imaging and diffusion tensor imaging for the diagnosis of liver fibrosis and inflammation. J Magn Reson Imaging 2008; 28: 89-95.
17. Wang Y, Ganger DR, Levitsky J, et al., Assessment of chronic hepatitis and fibrosis: comparison of MR elastography and diffusion-weighted imaging. AJR Am J Roentgenol 2011; 196: 553-561.
18. Luciani A, Vignaud A, Cavet M, et al., Liver cirrhosis: intravoxel incoherent motion MR imaging-pilot study. Radiology 2008; 249: 891-899.
19. Patel J, Sigmund EE, Rusinek H, Oei M, Babb JS, Taouli B,. Diagnosis of cirrhosis with intravoxel incoherent motion diffusion MRI and dynamic contrast-enhanced MRI alone and in combination: preliminary experience. J Magn Reson Imaging 2010; 31: 589-600.
20. LeBihan D, Breton E, Lallemand D, Aubin M-L, Vignaud J, Laval-Jeantet M,. Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology 1988; 168: 497-505.
21. LeBihan D,. Intravoxel incoherent motion perfusion MR imaging: a wake-up call. Radiology 2008; 249: 748-752.
22. Liau J, Lee J, Schroeder ME, Sirlin CB, Bydder M,. Cardiac motion in diffusion-weighted MRI of the liver: artifact and a method of correction. J Magn Reson Imaging 2012; 35: 318-327.
23. Murphy P, Wolfson T, Gamst A, Sirlin C, Bydder M,. Error model for reduction of cardiac and respiratory motion effects in quantitative liver DW-MRI. Magn Reson Med 2013; 70: 1460-1469.
24. Reeder SB, Hu HH, Sirlin CB,. Proton density fat-fraction: a standardized MR-based biomarker of tissue fat concentration. J Magn Reson Imaging 2012; 36: 1011-1014.
25. Tang A, Tan J, Sun M, et al., Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. Radiology 2013; 267: 422-431.
26. Bernstein M, King K, Zhou X,. Handbook of MRI pulse sequences. Burlington, MA: Elsevier Academic Press; 2004.
27. Kakite S, Dyvorne H, Besa C, et al., Hepatocellular carcinoma: short-term reproducibility of apparent diffusion coefficient and intravoxel incoherent motion parameters at 3.0T. J Magn Reson Imaging 2014; 39: 1-8.
28. Lee JT, Liau J, Murphy P, Schroeder ME, Sirlin CB, Bydder M,. Cross-sectional investigation of correlation between hepatic steatosis and IVIM perfusion on MR imaging. J Magn Reson Imaging 2012; 30: 572-578.
29. Hamilton G, Yokoo T, Bydder M, et al., In vivo characterization of the liver fat 1H MR spectrum. NMR Biomed 2011; 24: 784-790.
30. Lemke A, Laun FB, Simon D, Stieltjes B, Schad LR,. An in vivo verification of the intravoxel incoherent motion effect in diffusion-weighted imaging of the abdomen. Magn Reson Med 2010; 64: 1580-1585.
31. Le T-A, Chen J, Changchien C, et al., Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial. Hepatology 2012; 56: 922-932.
32. Hoofnagle JH, Van Natta ML, Kleiner DE, et al., Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2013; 38: 134-143.
33. Permutt Z, Le T, Peterson MR, et al., Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease-MRI accurately quantifies hepatic steatosis in NAFLD. Aliment Pharmacol Ther 2012; 36: 22-29.
34. Wang Y, Ganger DR, Levitsky J, et al., Assessment of chronic hepatitis and fibrosis: comparison of MR elastography and diffusion-weighted imaging. AJR Am J Roentgenol 2011; 196: 553-561.